预约演示
更新于：2026-04-09
Tovecimig
更新于：2026-04-09
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段临床2/3期 |
首次获批日期- |
最高研发阶段(中国)临床1/2期 |
特殊审评孤儿药 (美国)、快速通道 (美国) |
登录后查看时间轴
结构/序列
Sequence Code 41637
来源: *****
Sequence Code 1145509833
来源: *****
关联
8
项与 Tovecimig 相关的临床试验NCT07392957
A Phase IB/II Open-label Study of the Safety and Preliminary Efficacy of CTX-009 Administered Either as a Monotherapy or in Combination With CTX-471 in Patients With Recurrent Glioblastoma
NCT06548412
CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
NCT05506943
A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination With Paclitaxel Versus Paclitaxel Alone in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers Who Have Received One Prior Systemic Chemotherapy Regimen
100 项与 Tovecimig 相关的临床结果
登录后查看更多信息
100 项与 Tovecimig 相关的转化医学
登录后查看更多信息
100 项与 Tovecimig 相关的专利（医药）
登录后查看更多信息
9
项与 Tovecimig 相关的文献（医药）2024-12-01CANCER SCIENCE
Population pharmacokinetic model of ABL001 /CTX ‐009 (anti‐VEGF /DLL4 ) in adult cancer patients with solid tumor
Article
作者: Eom, Jaehyun ; Lee, Sangmi ; Huh, Ki Young ; Oh, Jaeseong ; Jeon, Juyeun ; You, Weon‐Kyoo ; Ahn, Jinhyung ; Na, Joo Young ; Yu, Kyung‐Sang
Abstract:
ABL001/CTX‐009 is a bispecific antibody targeting delta‐like ligand‐4 and vascular endothelial growth factor A. In this study, we developed a population pharmacokinetic (PK) model of ABL001/CTX‐009 in patients with solid tumors. A total of 712 plasma concentrations from 30 patients with relapsed or refractory solid tumors were collected from a phase 1 study (NCT03292783). A population PK model was developed using a nonlinear mixed‐effect method and was evaluated by graphical and numerical methods. Using the model, the steady‐state concentrations were simulated to compare weight‐based and fixed‐dose regimens and to find optimal dosing intervals. The PK of ABL001/CTX‐009 was well described by a two‐compartment model with a parallel first‐order and Michaelis–Menten elimination kinetics. Body weight was selected as a significant covariate on V1. Model evaluation results suggested that the model was adequate and robust with good precision. Simulations after administrations of fixed or weight‐based doses showed similar plasma concentrations. Additionally, 10 mg/kg for every other week and 15 mg/kg for every three‐week administration showed comparable plasma concentrations. In conclusion, the model well described the plasma concentrations of ABL001/CTX‐009 in patients with solid tumors. The simulation suggested that weight‐based dose and fixed dose can provide equivalent systemic exposure.
2024-09-22Future Oncology
COMPANION-002 A clinical trial of investigational drug CTX-009 plus paclitaxel vs paclitaxel in second line advanced BTC
Article
作者: Rosales, Minori ; Shroff, Rachna ; Aranha, Olivia ; Liao, Chih-Yi ; Kalyan, Aparna ; Pathak, Priyadarshini ; Sahin, Ilyas ; Gabrail, Nashat Y ; Shumway, Nathan ; Tran, Nguyen ; Majeed, Umair ; Hu, Zishuo ; El-Khoueiry, Anthony ; Borad, Mitesh ; Kamath, Suneel ; Kelley, Robin K ; Paulson, Andrew Scott ; Du, Lingling ; Hochster, Howard ; Goyal, Lipika ; Azad, Nilofer ; Heestand, Gregory ; Javle, Milind ; Iyer, Renuka ; Cosgrove, David
Treatment options for patients with biliary tract cancer are limited, and the prognosis is poor. CTX-009, a novel bispecific antibody targeting both DLL4 and VEGF-A, has demonstrated antitumor activity in patients with advanced cancers as both a monotherapy and in combination with chemotherapy. In a phase II study of patients with advanced biliary tract cancer who had received one or two prior therapies, CTX-009 with paclitaxel demonstrated a 37.5% overall response rate (ORR). Described here is the design of and rationale for COMPANION-002, a randomized phase II/III study, which will evaluate the safety and efficacy of CTX-009 in combination with paclitaxel versus paclitaxel alone as second-line treatment for patients with advanced biliary tract cancer. The primary end point is ORR, and crossover is allowed.Clinical Trial Registration: NCT05506943 (ClinicalTrials.gov).
2021-11-25Blood
Asciminib for CML: same target, new arrow
Communications
作者: Schiffer, Charles A.
The outlook for patients with chronic phase chronic myelogenous leukemia (CML) has improved dramatically since the development in the late 1990s of oral tyrosine kinase inhibitors (TKIs) targeting the ATP binding site of the BCR-ABL1 oncoprotein.Here, the authors address the management of patients in chronic phase previously treated with ≥ 2 TKIs in a randomized trial comparing asciminib and bosutinib, which is approved for use in this patient population.Ascinimib (previously known as ABL001) is a small mol. which binds to the myristoyl pocket located at a different site on the BCR-ABL1 protein, producing a conformational change that inhibits downstream signaling.
100 项与 Tovecimig 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| Vater壶腹癌 | 临床3期 | 美国 | 2023-01-09 | |
| 胆囊癌 | 临床3期 | 美国 | 2023-01-09 | |
| 肝内胆管癌 | 临床3期 | 美国 | 2023-01-09 | |
| 胆管癌 | 临床3期 | 美国 | - | |
| 胆道癌 | 临床3期 | 美国 | - | |
| 复发性胶质母细胞瘤 | 临床2期 | 美国 | 2026-04-30 | |
| 转移性胆道癌 | 临床2期 | 美国 | 2025-01-22 | |
| 转移性胆道癌 | 临床2期 | 美国 | 2025-01-22 | |
| 结肠癌 | 临床2期 | 美国 | 2022-12-08 | |
| 直肠癌 | 临床2期 | 美国 | 2022-12-08 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 40 | 顧襯蓋膚蓋膚鬱顧範網(鬱糧憲網膚廠遞顧鏇構) = 餘鬱壓膚鬱糧構選鏇鑰 網鏇醖鑰構構選齋鹽壓 (鬱夢願糧鏇鑰鹽膚餘膚 ) 更多 | 积极 | 2026-01-08 | |||
临床2期 | 40 | 廠廠鹽夢製網積醖觸獵(繭蓋鬱蓋顧鬱鹽觸觸糧) = 範鏇鬱獵積壓鏇蓋獵齋 窪窪範簾構積襯構餘艱 (築襯壓願窪鑰齋鹽糧遞 ) 更多 | 积极 | 2026-01-08 | |||
临床2/3期 | 胆道癌 二线 | - | Tovecimig + Paclitaxel | 壓糧遞淵夢願獵顧觸築(繭獵蓋廠構壓餘襯蓋構) = 觸鬱繭鬱範醖鬱遞範襯 衊窪窪築蓋窪淵糧糧壓 (窪構蓋蓋膚鑰鹹築遞蓋 ) 达到 更多 | 积极 | 2025-04-10 | |
Paclitaxel alone | 壓糧遞淵夢願獵顧觸築(繭獵蓋廠構壓餘襯蓋構) = 願廠遞築鑰構憲夢醖鬱 衊窪窪築蓋窪淵糧糧壓 (窪構蓋蓋膚鑰鹹築遞蓋 ) 达到 更多 | ||||||
临床2/3期 | 胆道癌 二线 | - | 鹹廠衊鏇憲餘構鏇鬱簾(夢窪願餘積鹽製範願獵) = 蓋糧簾願衊憲願顧艱憲 憲構繭壓壓廠廠鑰壓壓 (觸獵壓餘鏇蓋願襯構範 ) | 积极 | 2024-09-22 | ||
临床2期 | 胆道癌 二线 | 24 | 願繭鹽構築鬱遞鏇鹽願(夢襯窪艱齋憲構淵膚觸) = 壓遞齋鹽網鬱構繭衊壓 構壓廠醖憲觸遞鑰築構 (遞壓憲夢餘糧範糧獵願, 18.8 ~ 59.4) 更多 | 积极 | 2023-01-24 | ||
临床2期 | 24 | paclitaxel+ES104 | 顧鹹範鏇鏇衊構淵壓齋(鏇選窪廠淵築築壓願觸) = 淵繭築夢鬱願範艱膚簾 遞鬱鏇廠顧觸構鏇廠製 (網鏇遞網廠壓積憲壓顧 ) 更多 | 积极 | 2022-05-05 | ||
临床2期 | 24 | 選醖觸簾繭齋鑰築鏇糧(願夢顧鑰簾醖窪積願憲) = 簾鬱願廠廠鹽網遞觸襯 網鹽衊膚遞壓衊鑰壓範 (鹽遞艱醖鬱夢鹹鏇醖鹹 ) 更多 | 积极 | 2022-05-04 | |||
临床1期 | 45 | 鹽衊膚鏇願憲鏇淵衊廠(憲選選憲獵糧齋夢鏇構) = 10.0 and 12.5 mg/kg biweekly 鏇鏇糧鏇餘選壓積窪鏇 (艱簾餘壓網餘夢艱鬱廠 ) | 积极 | 2021-10-08 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用